六月 2026
- Home
- ORIC Pharmaceuticals
六月 2026的ORIC Pharmaceuticals市场份额分析
ORIC® is a science-driven, clinical stage company dedicated to developing novel therapies to improve patients’ lives by Overcoming Resistance In Cancer. We offer a collaborative, empowering culture that gives all employees the authority, responsibility and support to do cutting-edge work on advancing therapies for treatment-resistant cancers. Our culture and values support our mission, provide a […]
ORIC Pharmaceuticals(包含公司地区分支机构)
查看更多网站流量和参与度信息- oricpharma.com
ORIC Pharmaceuticals收入截至 六月 2026为 25M - 50M
ORIC Pharmaceuticals主要域名产生的收入
3 年中ORIC Pharmaceuticals主要域名的收入
ORIC Pharmaceuticals主要域名的收入
ORIC Pharmaceuticals热门域名的总访问量
了解ORIC Pharmaceuticals市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
ORIC Pharmaceuticals热门域名的平均访问时长
分析ORIC Pharmaceuticals参与度指标。
过去 3 个月的平均访问时长
子公司明细
ORIC Pharmaceuticals热门域名的平均页面浏览量
了解ORIC Pharmaceuticals如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
ORIC Pharmaceuticals 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻ORIC Pharmaceuticals, Inc. will attend event European Society for Medical Oncology (ESMO) Congress 2026 on Oct 23rd '26.SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) - ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced three poster presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.
七月 20, 2026阅读更多
新闻ORIC Pharmaceuticals, Inc. attended event 2026 American Association for Cancer Research (AACR) Annual Meeting on Apr 17th '26.SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) - ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts highlighting the potential of rinzimetostat (ORIC-944), a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer, have been accepted for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22, 2026 in San Diego, CA.
三月 17, 2026阅读更多
新闻ORIC Pharmaceuticals, Inc. attended event ESMO Asia Congress 2025 on Jul 1st '25.SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) - ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two late-breaking oral presentations highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore.
十二月 3, 2025阅读更多
查看 ORIC Pharmaceuticals 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
